Cargando…

Radiation Therapy for Advanced-Stage Hodgkin Lymphoma

The backbone of treatment for patients with advanced-stage Hodgkin lymphoma is systemic therapy. The use of radiation therapy as a component of combined-modality treatment in this setting is controversial. In this review, we describe the data in support of and against the use of radiation therapy fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Lockney, Natalie A., Yang, Joanna C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7557128/
https://www.ncbi.nlm.nih.gov/pubmed/33083642
http://dx.doi.org/10.1016/j.adro.2020.06.001
_version_ 1783594352562405376
author Lockney, Natalie A.
Yang, Joanna C.
author_facet Lockney, Natalie A.
Yang, Joanna C.
author_sort Lockney, Natalie A.
collection PubMed
description The backbone of treatment for patients with advanced-stage Hodgkin lymphoma is systemic therapy. The use of radiation therapy as a component of combined-modality treatment in this setting is controversial. In this review, we describe the data in support of and against the use of radiation therapy for stage III and IV Hodgkin lymphoma. Specifically, we review the data for the use of radiation therapy in the consolidation and partial-response settings, including for patients with initial bulky disease. We also discuss the use of radiation therapy in the era of more modern systemic therapies, including checkpoint inhibitors and brentuximab vedotin.
format Online
Article
Text
id pubmed-7557128
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-75571282020-10-19 Radiation Therapy for Advanced-Stage Hodgkin Lymphoma Lockney, Natalie A. Yang, Joanna C. Adv Radiat Oncol Critical Review The backbone of treatment for patients with advanced-stage Hodgkin lymphoma is systemic therapy. The use of radiation therapy as a component of combined-modality treatment in this setting is controversial. In this review, we describe the data in support of and against the use of radiation therapy for stage III and IV Hodgkin lymphoma. Specifically, we review the data for the use of radiation therapy in the consolidation and partial-response settings, including for patients with initial bulky disease. We also discuss the use of radiation therapy in the era of more modern systemic therapies, including checkpoint inhibitors and brentuximab vedotin. Elsevier 2020-06-20 /pmc/articles/PMC7557128/ /pubmed/33083642 http://dx.doi.org/10.1016/j.adro.2020.06.001 Text en © 2020 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Critical Review
Lockney, Natalie A.
Yang, Joanna C.
Radiation Therapy for Advanced-Stage Hodgkin Lymphoma
title Radiation Therapy for Advanced-Stage Hodgkin Lymphoma
title_full Radiation Therapy for Advanced-Stage Hodgkin Lymphoma
title_fullStr Radiation Therapy for Advanced-Stage Hodgkin Lymphoma
title_full_unstemmed Radiation Therapy for Advanced-Stage Hodgkin Lymphoma
title_short Radiation Therapy for Advanced-Stage Hodgkin Lymphoma
title_sort radiation therapy for advanced-stage hodgkin lymphoma
topic Critical Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7557128/
https://www.ncbi.nlm.nih.gov/pubmed/33083642
http://dx.doi.org/10.1016/j.adro.2020.06.001
work_keys_str_mv AT lockneynataliea radiationtherapyforadvancedstagehodgkinlymphoma
AT yangjoannac radiationtherapyforadvancedstagehodgkinlymphoma